Please ensure Javascript is enabled for purposes of website accessibility

Aprea Therapeutics Receives Breakthrough Therapy Designation for APR-246

By Taylor Carmichael - Jan 30, 2020 at 3:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drug candidate is in phase 3 trials as a treatment of myelodysplastic syndrome (MDS), which often leads to blood and bone marrow cancers.

Aprea Therapeutics (APRE) announced today that the Food and Drug Administration has given its breakthrough therapy designation to the company's lead drug candidate, APR-246. It is being tested in a cocktail with Azacitidine (a type of chemotherapy) to treat myelodysplastic syndrome (MDS), a condition that often progresses to leukemia. 

APR-246 is designed to help patients who have a genetic mutation in tp53, a key cancer-suppressing gene. This gene provides cells with the instructions for producing a protein (P53) that keeps cell division in check, thus suppressing cancers in the human body. When the gene mutates and stops working, cancer proliferates. P53 is the most common mutated gene in human cancers, occurring in approximately 50% of all tumors.   

DNA helix

Image source: Getty Images

Why is APR-246 a breakthrough therapy?

The FDA reserves its breakthrough therapy designation for drugs that treat serious conditions when early clinical trials indicate they are superior to existing therapies. Treatments that receive it are given an automatic fast-track through the regulatory review process.  

"Outcomes for MDS patients with a TP53 mutation are poor and there are no current therapeutic options specifically for these patients," said Aprea CEO Christian Schade. "We look forward to continued interaction with FDA regarding our ongoing Phase 3 clinical study and our clinical development program to advance APR-246." 

Aside from MDS, Aprea is testing APR-246 for acute myeloid leukemia (AML) and ovarian cancer.  It's the company's only molecule in clinical trials. The company is focusing all its research on developing drugs that reactivate the cancer-suppressing p53 protein. Aprea had its initial public offering last year and was one of the top-performing IPOs for 2019, ending the year up 131%. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aprea Therapeutics, Inc. Stock Quote
Aprea Therapeutics, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.